Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
复制标题
DOI：
10.1093/annonc/mds226
复制
发表时间：
2012-10-01
影响因子：
50.5
通讯作者：
Felip, E.
中科院分区：
文献类型：
--
作者：
Peters, S.;Adjei, A. A.;Felip, E.
原发性肺癌是仅次于非黑素细胞皮肤癌的最常见的恶性肿瘤，也是全球人类癌症死亡的主要原因[1]。自20世纪60年代以来，它一直是男性癌症死亡的最重要原因，但自20世纪90年代以来，它已与乳腺癌平起平坐，成为女性死亡的原因之一。肺癌在世界范围内的患病率和死亡率仍在上升。在发达国家，男性的肺癌死亡率已经开始下降，这反映出吸烟的减少，在大多数欧洲国家和美国，女性的肺癌死亡率正达到平台期--那里女性的肺癌死亡率正在接近男性。2012年，欧盟女性肺癌死亡人数预计将增加(+7%)[2]。
Primary lung cancer is the most common malignancy after non-melanocytic skin cancer, and the leading cause of human cancer deaths worldwide [1]. While it has been the most important cause of cancer mortality in men since the 1960s, it has equaled breast cancer as a cause of mortality in women since the 1990s. Lung cancer is still increasing both in prevalence and mortality worldwide. In developed countries, the latter has begun to decline in men, reflecting a decrease in smoking, and is reaching a plateau for women in most European countries and in the United States—where lung cancer death rates in women are approaching those of men. Lung cancer deaths in women are expected to increase (+ 7%) in the EU in 2012 [2].